白宫推出药品购买网站后，阿斯利康股价上涨3.6%。 来源：滚动播报 ...

Core Viewpoint - GSK is transitioning from American Depositary Receipts (ADRs) on Nasdaq to a direct listing of ordinary shares on the New York Stock Exchange, coinciding with the departure of CEO Emma Walmsley and the appointment of Luke Miels as her successor [1][3]. Company Developments - GSK's CEO Emma Walmsley will leave at the end of the year after nine years, having led the company through its demerger, which resulted in the formation of Haleon as a separate entity [1]. - Luke Miels, the current chief commercial officer, will take over as CEO, having previously been with AstraZeneca (AZ) [1]. Market Reactions - The announcement of GSK's move was positively received by investors, resulting in a 0.8% increase in shares on the following Monday [3]. - The shift to a direct listing is expected to attract new U.S. investors, particularly if AZ gains membership in the S&P 500 [3]. Industry Trends - There is a growing trend of UK-listed companies moving their primary listings to the U.S., with several notable companies, including BHP Group, Ferguson, and CRH, having made similar transitions recently [6][7][8][9]. - The movement of companies away from the London Stock Exchange (LSE) has raised concerns about the future of the UK market, especially as major firms like Flutter Entertainment and Arm Holdings have opted for U.S. listings [10][11][12]. Implications for AstraZeneca - AstraZeneca's potential move to the U.S. market has been a topic of discussion, with CEO Pascal Soriot expressing interest in relocating the company's stock market listing [4][5]. - Despite concerns, AZ emphasized that its status as a UK-listed company would remain unchanged, aiming to attract a broader mix of global investors [15]. - AZ's current price-to-earnings ratio is competitive compared to both European and U.S. peers, indicating that the move is not necessarily driven by a desire for a higher stock rating [16].

Core Insights - AstraZeneca's stock has shown strong performance, rising 3.49% for three consecutive days, indicating investor confidence amid market volatility [1] - The company plans to directly list on the New York Stock Exchange, replacing its current American Depositary Receipts (ADR) on NASDAQ, aiming to attract more global investors while maintaining its UK listing status [1] - AstraZeneca intends to invest $50 billion in manufacturing and R&D in the U.S. by 2030 to maintain its market leadership amid increasing competition in generics [1] Market Position - The U.S. is AstraZeneca's largest single market, contributing over 40% of its revenue, with a goal to achieve $80 billion in annual revenue by 2030 [2] - The company has reported positive clinical trial results for its HER2-positive early breast cancer drug, trastuzumab, enhancing its innovative drug portfolio and potentially transforming treatment options [2] - AstraZeneca's strategic shift towards the U.S. market is expected to bolster its appeal in global capital markets and position it favorably in international competition [2]

Group 1 - AbCellera Biologics Inc. (ABCL) has shown strong year-to-date performance, with a return of approximately 66.2%, outperforming the Medical sector, which has lost an average of 2.7% [4] - The Zacks Rank for AbCellera Biologics Inc. is currently 2 (Buy), indicating a positive earnings outlook based on earnings estimates and revisions [3][4] - The Zacks Consensus Estimate for ABCL's full-year earnings has increased by 8.3% over the past quarter, reflecting improved analyst sentiment [4] Group 2 - AbCellera Biologics Inc. is part of the Medical - Biomedical and Genetics industry, which consists of 482 stocks and currently ranks 78 in the Zacks Industry Rank [6] - The average return for stocks in the Medical - Biomedical and Genetics industry this year is 3.2%, indicating that ABCL is performing better than its peers in this specific industry [6] - Another notable stock in the Medical sector, Astrazeneca (AZN), has returned 13.1% year-to-date and also holds a Zacks Rank of 2 (Buy) [5][6] Group 3 - Investors should continue to monitor AbCellera Biologics Inc. and Astrazeneca for potential sustained strong performance in the Medical sector [7]

AstraZeneca's move to upgrade its listing in the U.S. risks pulling liquidity away from London's stock market and could pave the way for other large companies to follow suit, analysts, investors and a... ...

Group 1: Granolas Sector Analysis - The Granolas sector, which includes major European companies, has underperformed the European market index by approximately 25% since early 2024, with its market capitalization dropping from 27% to 20% of the overall European market [2] - Despite weak stock performance, Granolas' earnings have not deteriorated, with an expected earnings growth rate of 8% for 2025, while overall European market earnings are projected to remain flat [2] - The valuation issues of Granolas have been corrected, with the current price-to-earnings ratio at a 6% discount compared to the median of the past 10 years, indicating a return to reasonable levels [2] - Granolas' free cash flow yield has improved, and cash reserves on the balance sheet increased from €91 billion in 2023 to €106 billion in 2024, with stock buybacks projected to rise from €23 billion in 2023 to an annualized €36 billion in 2025 [2] Group 2: French Stock Market Outlook - The French stock market has underperformed the market by about 15% over the past two years, with bank stocks lagging behind Eurozone peers by as much as 30% [4] - Currently, the French stock market is trading at a significant discount compared to the STOXX 50 index, a situation historically seen only during major crises [4] - Morgan Stanley believes that the long-term bond yields in France are unlikely to continue rising, and the negative impact from the government's failure to pass a confidence vote may temporarily dissipate, presenting attractive investment opportunities [4] - Despite high uncertainty, including potential future confidence votes, there is a possibility of reaching a budget plan acceptable to the market, and any negative impact from re-elections on risk assets may be short-lived [4]

Core Viewpoint - The company has terminated its collaboration with AstraZeneca on the development, production, and commercialization of the ChAdOx1 adenovirus vector COVID-19 vaccine due to changes in the epidemic strain and market environment, as well as resource allocation considerations [1] Group 1: Collaboration Termination - The termination of the collaboration is a cautious decision based on the evolving COVID-19 vaccine landscape and market conditions [1] - The company has signed a License Termination Agreement with AstraZeneca [1] Group 2: Future Focus - The company currently has nearly 30 projects in development, covering important categories such as multivalent vaccines and innovative vaccines [1] - Future resource allocation will concentrate on the research and industrialization of multivalent vaccines, adult vaccines, innovative vaccines, and therapeutic vaccines to enhance core competitiveness [1]

来源：市场资讯 这是一次重大调整，旨在借助美国资本市场的深度和流动性，扩大投资者基础，提升股票吸引力。此方 案仍需在即将于2025年11月3日召开的普通股东大会上获得批准。 从二级市场反应来看，投资者对该消息表现出谨慎乐观的态度。9月29日，阿斯利康（伦敦交易所上 市）股价收涨0.8%，公司市值约为1710亿英镑。 （来源：求实药社） 据路透社消息，阿斯利康9月29日公布计划，将于2026年2月2日起在纽约证券交易所实现普通股直接上 市，以取代目前的美国存托凭证（ADR）交易模式。 整体来看，阿斯利康此举既体现了对美国资本市场的倚重，也再次重申其英国总部和伦敦上市地位。通 过纽交所直接上市，公司有望获得更广泛的资本关注和更高的市场流动性，而伦敦与斯德哥尔摩的保留 上市则稳固了其多元化布局。这是一场在坚守本土根基与追求全球成长之间的平衡之举。 未来若成功执行，该策略或将成为其他大型英国或欧洲跨国公司在资本市场布局上的参考样板，也可能 对英国资本市场在全球竞争中的地位与结构产生深远影响。 阿斯利康同时表示，将继续保留英国总部与伦敦主要上市地位，并维持在斯德哥尔摩挂牌。作为伦敦市 值最高的制药公司，这一表态缓解了外 ...

Core Insights - The pharmaceutical industry lobbying group PhRMA plans to launch a new website, AmericasMedicines.com, in January 2025 to enable patients to purchase prescription drugs directly from manufacturers, bypassing pharmacy benefit managers (PBMs) to reduce drug prices and simplify the purchasing process [1] - This initiative is a response to pressure from the Trump administration to lower U.S. drug prices, with President Trump having previously urged major pharmaceutical companies to align U.S. prescription drug prices with those of other developed countries [1] - The direct-to-consumer (DTC) sales model is gaining traction, with companies like Eli Lilly, Pfizer, and AstraZeneca launching their own platforms, and Novartis announcing a direct sales platform set to launch on November 1, offering significant discounts on certain medications [1] Industry Developments - PhRMA announced a total investment of $500 billion in domestic production and infrastructure, which is expected to generate $1.2 trillion in economic output and create over 100,000 jobs [2]

Core Viewpoint - AstraZeneca plans to switch to a direct listing of its shares in the United States to capitalize on the booming U.S. stock market [1] Group 1: Company Strategy - The company aims to maximize gains from the U.S. stock market through this direct listing approach [1]